Workflow
Vertex(VRTX)
icon
Search documents
Vertex (VRTX) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
ZACKS· 2024-10-30 14:20
In its upcoming report, Vertex Pharmaceuticals (VRTX) is predicted by Wall Street analysts to post quarterly earnings of $4.13 per share, reflecting an increase of 1.2% compared to the same period last year. Revenues are forecasted to be $2.68 billion, representing a year-over-year increase of 7.8%. The consensus EPS estimate for the quarter has been revised 1.2% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial e ...
Vertex Pharmaceuticals (VRTX) Stock Drops Despite Market Gains: Important Facts to Note
ZACKS· 2024-10-28 23:06
Vertex Pharmaceuticals (VRTX) closed at $476.37 in the latest trading session, marking a -0.28% move from the prior day. The stock trailed the S&P 500, which registered a daily gain of 0.27%. Meanwhile, the Dow experienced a rise of 0.65%, and the technology-dominated Nasdaq saw an increase of 0.26%.Shares of the drugmaker witnessed a gain of 3.2% over the previous month, beating the performance of the Medical sector with its loss of 4.14% and the S&P 500's gain of 2%.Market participants will be closely fol ...
Why Vertex Pharmaceuticals (VRTX) Dipped More Than Broader Market Today
ZACKS· 2024-10-21 23:06
The most recent trading session ended with Vertex Pharmaceuticals (VRTX) standing at $478.09, reflecting a -1.02% shift from the previouse trading day's closing. This change lagged the S&P 500's 0.18% loss on the day. At the same time, the Dow lost 0.8%, and the tech-heavy Nasdaq gained 0.27%.Prior to today's trading, shares of the drugmaker had gained 3.89% over the past month. This has outpaced the Medical sector's loss of 3.03% and lagged the S&P 500's gain of 4.46% in that time.Market participants will ...
Vertex Pharmaceuticals (VRTX) Ascends But Remains Behind Market: Some Facts to Note
ZACKS· 2024-10-14 23:06
Vertex Pharmaceuticals (VRTX) closed the latest trading day at $484.94, indicating a +0.67% change from the previous session's end. This move lagged the S&P 500's daily gain of 0.77%. On the other hand, the Dow registered a gain of 0.47%, and the technology-centric Nasdaq increased by 0.87%. The drugmaker's shares have seen a decrease of 0.75% over the last month, surpassing the Medical sector's loss of 3% and falling behind the S&P 500's gain of 4.87%. Analysts and investors alike will be keeping a close e ...
Vertex Pharmaceuticals (VRTX) Surpasses Market Returns: Some Facts Worth Knowing
ZACKS· 2024-09-30 23:06
Vertex Pharmaceuticals (VRTX) closed at $465.08 in the latest trading session, marking a +0.48% move from the prior day. This move outpaced the S&P 500's daily gain of 0.42%. Meanwhile, the Dow experienced a rise of 0.04%, and the technology-dominated Nasdaq saw an increase of 0.38%. The drugmaker's stock has dropped by 6.66% in the past month, falling short of the Medical sector's loss of 2.49% and the S&P 500's gain of 2.06%. The upcoming earnings release of Vertex Pharmaceuticals will be of great interes ...
Wall Street Analysts See Vertex (VRTX) as a Buy: Should You Invest?
ZACKS· 2024-09-26 14:31
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though? Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Vertex Pharmaceuticals (VRTX) . Vertex currently has an average ...
Vertex Pharmaceuticals Incorporated (VRTX) Management presents at Cantor Global Healthcare Conference (Transcript)
Seeking Alpha· 2024-09-17 15:52
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Cantor Global Healthcare Conference September 17, 2024 9:10 AM ET Company Participants Susie Lisa - SVP, IR Manisha Pai - Executive Director, IR Conference Call Participants Olivia Brayer - Cantor Fitzgerald Olivia Brayer Joining us this morning at our Cantor Global Healthcare Conference. Really excited to have another year of it. My name is Olivia Brayer. I'm a senior Biotech Analyst here at Cantor. And we're really excited to have the Vertex IR team with u ...
Is Most-Watched Stock Vertex Pharmaceuticals Incorporated (VRTX) Worth Betting on Now?
ZACKS· 2024-09-13 14:02
Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Shares of this drugmaker have returned +1.4% over the past month versus the Zacks S&P 500 composite's +4.9% change. The Zacks Medical - Biomedical and Genetics industry, to which Vertex belongs, has gained 3.7% over this period. Now the key question is: Where could the stock be headed in ...
Here's How to Play Vertex (VRTX) Stock After Q2 Loss, Price Dip
ZACKS· 2024-08-08 16:11
Vertex Pharmaceuticals Incorporated (VRTX) reported second-quarter 2024 results on Aug 1. Adjusted loss per share of $12.83 was wider than the Zacks Consensus Estimate of a loss of $11.50. The significant loss in the quarter was due to costs related to the $4.9 billion acquisition of Alpine Immune Sciences closed in May. Revenues of $2.65 billion were in line with the Zacks Consensus Estimate. Total revenues rose 6% year over year, primarily driven by higher sales of its cystic fibrosis (CF) drug Trikafta/K ...
Compared to Estimates, Vertex (VRTX) Q2 Earnings: A Look at Key Metrics
ZACKS· 2024-08-02 23:01
Core Insights - Vertex Pharmaceuticals reported $2.65 billion in revenue for Q2 2024, a year-over-year increase of 6.1% [1] - The company experienced an EPS of -$12.83, a significant decline from $3.89 a year ago, with an EPS surprise of -11.57% [1][2] - The reported revenue was in line with the Zacks Consensus Estimate, showing a slight surprise of -0.08% [1] Revenue Breakdown - Geographic Revenues in the United States reached $1.61 billion, exceeding the estimated $1.59 billion, reflecting a +7.1% change year-over-year [3] - Geographic Revenues outside the United States were $1.03 billion, matching the analyst estimate and showing a +4.7% change from the previous year [4] - Revenues from the product Trikafta/Kaftrio totaled $2.45 billion, aligning with the seven-analyst average estimate and representing a +9.3% year-over-year increase [5] - Revenues from other CF products amounted to $196.40 million, surpassing the two-analyst average estimate of $179.54 million [6] Stock Performance - Vertex shares have returned +7.6% over the past month, contrasting with the Zacks S&P 500 composite's -0.4% change [6] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [6]